Barclays reiterated coverage of Snap with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/11/2025 | Buy → Neutral | Guggenheim | |
| 2/5/2025 | Overweight | Barclays | |
| 2/5/2025 | $15.00 → $11.00 | Overweight → Equal Weight | Wells Fargo |
| 10/23/2024 | $17.00 | Mkt Perform → Mkt Outperform | JMP Securities |
| 9/20/2024 | $11.00 | Neutral | B. Riley Securities |
| 9/5/2024 | $8.00 | Neutral | Cantor Fitzgerald |
| 8/2/2024 | Buy → Hold | HSBC Securities | |
| 7/23/2024 | $12.00 → $16.00 | Underweight → Equal-Weight | Morgan Stanley |
Snap Inc. (NYSE:SNAP) announced today at the Augmented World Expo 2025 that it is launching lightweight, immersive Specs in 2026. Specs are an ultra-powerful wearable computer integrated into a lightweight pair of glasses, featuring see-through Lenses that enhance the physical world with digital experiences. Snap's all-new Specs are uniquely positioned to understand the world through advanced machine learning, bring AI assistance into three-dimensional space, enable shared games and experiences with friends, and provide a flexible and powerful workstation for browsing, streaming, and more. "We believe the time is right for a revolution in computing that naturally integrates our digital
First quarter revenue increased 14% year-over-year to $1,363 million Daily Active Users increased 9% year-over-year to 460 million Net loss improved 54% year-over-year to $140 million Adjusted EBITDA improved 137% year-over-year to $108 million Snap Inc. (NYSE:SNAP) today announced financial results for the quarter ended March 31, 2025. "We surpassed an important milestone in Q1, with our community growing to over 900 million monthly active users," said Evan Spiegel, CEO. "Quarterly revenue increased 14% year-over-year, driven by the progress we have made with our direct-response advertising solutions, continued momentum in driving performance for small and medium sized businesses, and
Snap Inc. (NYSE:SNAP) will hold its quarterly conference call to discuss first quarter 2025 financial results on Tuesday, April 29, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible on Snap Inc.'s Investor Relations website for at least 90 days at: http://investor.snap.com. About Snap Inc. Snap Inc. is a technology company. We believe the camera presents the greatest opportunity to improve the way people live and communicate. We contribute to human progress by empowering people to express themselves, live in the moment, learn about the world, and have fun together. For more information, visit snap.com. View source
Guggenheim downgraded Snap from Buy to Neutral
Barclays reiterated coverage of Snap with a rating of Overweight
Wells Fargo downgraded Snap from Overweight to Equal Weight and set a new price target of $11.00 from $15.00 previously
For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu
For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). Pemgarda is
For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains
SD - Snap Inc (0001564408) (Filer)
S-8 - Snap Inc (0001564408) (Filer)
10-Q - Snap Inc (0001564408) (Filer)